Loading
Countries negotiate secret discounts, so nobody knows what anyone actually pays for a cancer drug. Sharing real prices between public buyers would strengthen every negotiation.
Confidential rebates mean list prices are fiction and payers negotiate blind, a situation that the WHO Fair Pricing Forum and the Oslo Medicines Initiative have identified as one of the main drivers of high prices. The proposal is a treaty-level or coalition arrangement in which public payers deposit net prices per oncology product into a secure registry visible to other participating payers (not to the public or industry), with aggregate transparency published annually. Beneluxa and the Nordic Pharmaceutical Forum already share some information.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.